Drug Profile
Research programme: rhinovirus replication inhibitors - Bristol-Myers Squibb
Latest Information Update: 16 Jan 2008
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Small molecules
- Mechanism of Action Rhinovirus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Rhinovirus infections
Most Recent Events
- 31 May 2004 Phase-I clinical trials in Rhinovirus infections in USA (unspecified route)